
08/22/2025
Now this is great!
A new study by University of Florida researchers and collaborators has found that a popular class of weight loss drugs is associated with lower cancer risk.
Published today in JAMA Oncology, the large observational study used real-world data from OneFlorida+, a powerful multi-state resource of anonymous health records created by the UF CTSI and the UF Health Cancer Center. Researchers compared cancer risk in 43,317 adults with obesity or who were overweight who were using the weight loss drugs with 43,315 who were not.
Researchers found that GLP-1 medications such as Ozempic and Mounjaro were associated with a 17% lower cancer risk compared to non-users. Cancer incidence was lower for 12 of 13 obesity-related cancers, plus lung cancer. In particular, taking GLP-1 medications was associated with a reduced risk of endometrial and ovarian cancers and meningioma, but researchers noted an increased risk of kidney cancer.
Learn more: https://www.medpagetoday.com/hematologyoncology/othercancers/117100